Scholarlink

Background <p><i>Acinetobacter baumannii</i> is a notorious clinical pathogen that predominantly causes nosocomial infections. The multidrug resistant <i>Acinetobacter baumannii</i> clinical isolates are becoming more prevalent on a global scale. In this study, we aimed to determine the potential synergistic antibacterial activity of contezolid in combination with polymyxin B nonapeptide (PBNP) against various <i>A. baumannii</i> strains.</p> Results <p>Contezolid, a commonly-used agents targeting Gram-positive bacteria, in combination with PBNP (CP) was used to explore the potential synergistic antibacterial activity against <i>A. baumannii</i> in vitro and <i>Caenorhabditis elegans</i> models. We found that CP treatment exhibited a strong synergistic effect on <i>A. baumannii</i> or multidrug resistant <i>A. baumannii</i>. CP also inhibited the biofilm formation and alter morphology of <i>A. baumannii</i> compared to the control group. Moreover, the residual bacteria were significantly decreased in the CP-treated murine alveolar macrophages (MH-S). Importantly, CP treatment improved the survival of <i>C. elegans</i> compared to the control or monotherapy group.</p> Conclusions <p>This strategy improved antibacterial activity spectrum of agents targeting Gram-positive bacteria like contezolid. Nevertheless, CP combination therapy requires further validation in mammalian infection models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Contezolid and polymyxin B nonapeptide combination reveals antibacterial synergy against multidrug-resistant Acinetobacter baumannii strains

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Danrui Hao,
  • Yuhang Huang,
  • Tianzhu Zhao,
  • Runyu Wang,
  • Wei Jiang,
  • Xiangting Yuan,
  • Xinrong Wang,
  • Yiwen Chu,
  • Kelei Zhao,
  • Ting Huang,
  • Zhenxing Wang

摘要

Background

Acinetobacter baumannii is a notorious clinical pathogen that predominantly causes nosocomial infections. The multidrug resistant Acinetobacter baumannii clinical isolates are becoming more prevalent on a global scale. In this study, we aimed to determine the potential synergistic antibacterial activity of contezolid in combination with polymyxin B nonapeptide (PBNP) against various A. baumannii strains.

Results

Contezolid, a commonly-used agents targeting Gram-positive bacteria, in combination with PBNP (CP) was used to explore the potential synergistic antibacterial activity against A. baumannii in vitro and Caenorhabditis elegans models. We found that CP treatment exhibited a strong synergistic effect on A. baumannii or multidrug resistant A. baumannii. CP also inhibited the biofilm formation and alter morphology of A. baumannii compared to the control group. Moreover, the residual bacteria were significantly decreased in the CP-treated murine alveolar macrophages (MH-S). Importantly, CP treatment improved the survival of C. elegans compared to the control or monotherapy group.

Conclusions

This strategy improved antibacterial activity spectrum of agents targeting Gram-positive bacteria like contezolid. Nevertheless, CP combination therapy requires further validation in mammalian infection models.